Emergence of IncHI2 Plasmid-Harboring blaNDM-5 from Porcine Escherichia coli Isolates in Guangdong, China

Carbapenem resistance has posed potential harmful risks to human and animals. The objectives of this study were to understand the prevalence of blaNDM-5 in pigs and investigate the molecular characteristics of NDM-5-producing Escherichia coli isolates in Guangdong province in China. Carbapenem-resistant E. coli isolates were isolated from pigs and obtained using MacConkey plates containing 0.5 mg/L meropenem. Conjugation assay and antimicrobial susceptibility testing were conducted for the isolates and their transconjugants. Whole-genome sequence (WGS) was used to analyze the plasmid genetic feature. A total of five blaNDM-5-carrying E. coli isolates were obtained in the present investigations. They belonged to five ST types. The blaNDM-5 genes were found to be in IncX3 and IncHI2 plasmid. The IncX3 plasmid was 46,161 bp in size and identical to other reports. IncHI2 plasmid was 246,593 bp in size and similar to other IncHI2-ST3 plasmids. It consisted of a typical IncHI2 plasmid backbone region and a multiresistance region (MRR). The blaNDM-5 was closely associated with the IS3000-ISAba125-blaNDM-5-bleMBL-trpF-tat-IS26 unit. We first reported the blaNDM-5-carrying IncHI2 in E. coli isolates recovered from pigs and revealed the molecular characterization. Continued surveillance for the dissemination of blaNDM-5 among food-producing animals is required.

Download Full-text

Dissemination of Blandm-5 in Escherichia Coli via the Incx3 Plasmid From Different Regions in China

10.21203/rs.3.rs-254667/v1 ◽

2021 ◽

Author(s):

Xiaofeng Hu ◽

Lang Yang ◽

Nian Dong ◽

Yanfeng Lin ◽

Ling Zhang ◽

...

Keyword(s):

Escherichia Coli ◽

Blot Hybridization ◽

Carbapenem Resistance ◽

Southern Blot Hybridization ◽

Control Measures ◽

Rrna Gene ◽

Limited Information ◽

E Coli ◽

Carbapenem Resistant ◽

Antimicrobial Resistance Genes

Abstract Background: Recently, the spread of NDM-5-producing Escherichia coli has become a severe challenge in clinical therapy, which necessitates reliable detection and surveillance methods. However, limited information is available regarding the prevalence and dissemination of the blaNDM-5 gene in Escherichia coli in China. Therefore, we investigated the dissemination of the blaNDM-5 gene in carbapenem-resistant Escherichia coli isolates from different regions in China.Methods: A total of 1,180 carbapenem-resistant enterobacteriaceae strains were obtained from patients admitted to the 20 sentinel hospitals in eight cities. Strains positive for blaNDM-5 were detected using the Vitek 2 compact system, 16S rRNA gene sequencing, PCR, the S1-pulsed-field gel electrophoresis assay, and Southern blot hybridization. The horizontal-transfer capability of the blaNDM gene was assessed by filter mating with a standard E. coli J53 azide-resistant strain as the recipient. Genotyping, susceptibility testing, and whole genome sequencing were performed. Results: Seven strains of blaNDM-5-positive E.coli was detected in 1180 clinical strains from different regions in China. The blaNDM-5-carrying strains showed resistance to multiple tested antibiotics and belonged to two widespread sequence types, ST167 and ST405. Antimicrobial resistance genes including blaCTX-M, blaOXA, blaCMY, and two novel blaTEM variants (blaTEM-230 and blaTEM-231) were also identified. Southern blotting located the blaNDM-5 gene on 46-kb IncX3 plasmids in all isolates, which showed only two single nucleotide differences between EJN003 and the other strains. Conclusions: This study further confirms the increasing occurrence of blaNDM-5-carrying IncX3 plasmids and the dissemination of carbapenem resistance in E. coli isolates via the plasmid from different parts in China, which warrants stringent surveillance and control measures.

Download Full-text

Clinical and Microbiological Characteristics of a Community-Acquired Carbapenem-Resistant Escherichia coli ST410 Isolate Harbouring blaNDM-5-Encoding IncX3-Type Plasmid From Blood

Frontiers in Medicine ◽

10.3389/fmed.2021.658058 ◽

2021 ◽

Vol 8 ◽

Author(s):

Ji-Na Gu ◽

Lin Chen ◽

Xing-Bei Weng ◽

Xiao-Yan Yang ◽

Dan-Mei Pan

Keyword(s):

Escherichia Coli ◽

Antimicrobial Susceptibility ◽

Screening Test ◽

Faecal Sample ◽

Sequence Data ◽

Control Measures ◽

Whole Genome Sequence ◽

E Coli ◽

Carbapenem Resistant ◽

Microbiological Characteristics

Objectives: The aim of this research was to investigate the clinical and microbiological characteristics of a case of community-acquired carbapenem-resistant Escherichia coli isolated from a patient with a bloodstream infection in China.Methods:Escherichia coli Huamei202001 was recovered from the first blood culture from a patient hospitalised in China. An antimicrobial susceptibility test was performed, and the genome was sequenced on an Illumina HiSeq X 10 platform with a 150-bp paired-end approach. The generated sequence reads were assembled using Unicycler, and the whole genome sequence data were analysed using bioinformatics tools. Moreover, the patient and her main family members obtained a faecal sample screening test for CRE, the positive strain was further isolated and the identification and antimicrobial susceptibility testing was performed.Results:Escherichia coli Huamei202001 belonged to sequence type 410. In addition, a blaNDM-5-encoding IncX3-type plasmid was responsible for the spreading of carbapenem resistance. Only the patient was detected as having a positive faecal sample screening test for CRE. Strain Fec01 was identified as E. coli, and the antibiotic susceptibility profile was the same as that of E. coli Huamei202001.Conclusions:Escherichia coli Huamei202001 is defined as community-acquired carbapenem-resistant Enterobacteriaceae. The clone ST410 that harbours the blaNDM-5-encoding IncX3-type plasmid is causing new high-risk clones globally. Thus, infection control measures should be strengthened to curb the dissemination of IncX3.

Download Full-text

Activity of Cefiderocol, Ceftazidime-Avibactam, and Eravacycline against Carbapenem-Resistant Escherichia coli Isolates from the United States and International Sites in Relation to Clonal Background, Resistance Genes, Coresistance, and Region

Antimicrobial Agents and Chemotherapy ◽

10.1128/aac.00797-20 ◽

2020 ◽

Vol 64 (10) ◽

Cited By ~ 1

Author(s):

Brian D. Johnston ◽

Paul Thuras ◽

Stephen B. Porter ◽

Melissa Anacker ◽

Brittany VonBank ◽

...

Keyword(s):

Escherichia Coli ◽

Carbapenem Resistance ◽

The United States ◽

Asia Pacific ◽

Beta Lactamase ◽

Content Type ◽

Beta Lactamases ◽

E Coli ◽

Carbapenem Resistant ◽

Primary Agent

ABSTRACT Emerging carbapenem resistance in Escherichia coli, including sequence type 131 (ST131), the leading cause of extraintestinal E. coli infections globally, threatens therapeutic efficacy. Accordingly, we determined broth microdilution MICs for three distinctive newer agents, i.e., cefiderocol (CFDC), ceftazidime-avibactam (CZA), and eravacycline (ERV), plus 11 comparators, against 343 carbapenem-resistant (CR) clinical E. coli isolates, then compared susceptibility results with bacterial characteristics and region. The collection comprised 203 U.S. isolates (2002 to 2017) and 141 isolates from 17 countries in Europe, Latin America, and the Asia-West Pacific region (2003 to 2017). Isolates were characterized for phylogenetic group, resistance-associated sequence types (STs) and subsets thereof, and relevant beta-lactamase-encoding genes. CFDC, CZA, and ERV exhibited the highest percent susceptible (82% to 98%) after tigecycline (TGC) (99%); avibactam improved CZA's activity over that of CAZ (11% susceptible). Percent susceptible varied by phylogroup and ST for CFDC and CZA (greatest in phylogroups B2, D, and F, and in ST131, ST405, and ST648). Susceptibility also varied by resistance genotype, being higher with the Klebsiella pneumoniae carbapenemase (KPC) for CZA, lower with metallo-beta-lactamases for CFDC and CZA, and higher with the beta-lactamase CTX-M for ERV. Percent susceptible also varied by global region for CZA (lower in Asia-Pacific) and by U.S. region for ERV (lower in the South and Southeast). Although resistance to comparators often predicted reduced susceptibility to a primary agent (especially CFDC and CZA), even among comparator-resistant isolates the primary-agent-susceptible fraction usually exceeded 50%. These findings clarify the likely utility of CFDC, CZA, and ERV against CR E. coli in relation to multiple bacterial characteristics and geographical region.

Download Full-text

Activity of Imipenem-Relebactam against Carbapenem-Resistant Escherichia coli Isolates from the United States in Relation to Clonal Background, Resistance Genes, Coresistance, and Region

Antimicrobial Agents and Chemotherapy ◽

10.1128/aac.02408-19 ◽

2020 ◽

Vol 64 (5) ◽

Cited By ~ 2

Author(s):

Brian D. Johnston ◽

Paul Thuras ◽

Stephen B. Porter ◽

Melissa Anacker ◽

Brittany VonBank ◽

...

Keyword(s):

United States ◽

Escherichia Coli ◽

Carbapenem Resistance ◽

The United States ◽

Resistance Mechanisms ◽

Beta Lactamase ◽

Content Type ◽

E Coli ◽

Highly Active ◽

Carbapenem Resistant

ABSTRACT Imipenem-relebactam (I-R) is a recently developed carbapenem–beta-lactamase inhibitor combination agent that can overcome carbapenem resistance, which has now emerged in Escherichia coli, including sequence type 131 (ST131) and its fluoroquinolone-resistant H30R subclone, the leading cause of extraintestinal E. coli infections globally. To clarify the likely utility of I-R for carbapenem-resistant (CR) E. coli infections in the United States, we characterized 203 recent CR clinical E. coli isolates from across the United States (years 2002 to 2017) for phylogroup, clonal group (including ST131, H30R, and the CTX-M-15-associated H30Rx subset within H30R), relevant beta-lactamase genes, and broth microdilution MICs for I-R and 11 comparator agents. Overall, I-R was highly active (89% susceptible), more so than all comparators except tigecycline and colistin (both 99% susceptible). I-R’s activity varied significantly in relation to phylogroup, clonal background, resistance genotype, and region. It was greatest among phylogroup B2, ST131-H30R, H30Rx, Klebsiella pneumoniae carbapenemase (KPC)-positive, and northeast U.S. isolates and lowest among phylogroup C, New Delhi metallo-β-lactamase (NDM)-positive, and southeast U.S. isolates. Relebactam improved imipenem’s activity against CR isolates within each phylogroup—especially groups A, B1, and B2—and particularly against isolates containing KPC. I-R remained substantially active against isolates coresistant to comparator agents, albeit somewhat less so than against the corresponding susceptible isolates. These findings suggest that I-R should be useful for treating most CR E. coli infections in the United States, largely independent of coresistance, although this likely will vary in relation to the local prevalence of specific E. coli lineages and carbapenem resistance mechanisms.

Download Full-text

Synergistic Activity of Equol and Meropenem against Carbapenem-Resistant Escherichia coli

Antibiotics ◽

10.3390/antibiotics10020161 ◽

2021 ◽

Vol 10 (2) ◽

pp. 161

Author(s):

Hye-Rim Kim ◽

Yong-Bin Eom

Keyword(s):

Escherichia Coli ◽

Synergistic Effect ◽

Bacterial Infections ◽

Treatment Options ◽

Carbapenem Resistance ◽

Bacterial Biofilm ◽

Pcr Analysis ◽

Synergistic Activity ◽

E Coli ◽

Carbapenem Resistant

The emergence of carbapenem-resistant Enterobacterales (CRE) seriously limits treatment options for bacterial infections. Combined drugs are an effective strategy to treat these resistant strains. This study aimed to evaluate the synergistic effect of equol and meropenem against carbapenem-resistant Escherichia coli. First, this study investigated the antibacterial activity of carbapenems on clinically isolated E. coli strains by analyzing the minimum inhibitory concentrations (MICs). The E. coli strains were all resistant to carbapenem antibiotics. Therefore, we confirmed the cause of carbapenem resistance by detecting blaKPC and blaOXA-48 among the carbapenemase genes using polymerase chain reaction (PCR) analysis. Checkerboard and time-kill analyses confirmed that equol restored the susceptibility of carbapenem-resistant E. coli to meropenem. Also, the transcription levels of specific carbapenemase genes in E. coli were significantly suppressed by equol. The study also evaluated the anti-virulence effects of equol on bacterial biofilm and motility through phenotypic and genotypic analyses. In conclusion, our results revealed that equol had a synergistic effect with meropenem on carbapenem-resistant E. coli. Therefore, this study suggests that equol is a promising antibiotic adjuvant that prevents the expression of carbapenemases and virulence factors in carbapenem-resistant E. coli.

Download Full-text

Plasmid-Mediated Imipenem-Hydrolyzing Enzyme KPC-2 among Multiple Carbapenem-Resistant Escherichia coli Clones in Israel

Antimicrobial Agents and Chemotherapy ◽

10.1128/aac.00438-06 ◽

2006 ◽

Vol 50 (9) ◽

pp. 3098-3101 ◽

Cited By ~ 115

Author(s):

Shiri Navon-Venezia ◽

Inna Chmelnitsky ◽

Azita Leavitt ◽

Mitchell J. Schwaber ◽

David Schwartz ◽

...

Keyword(s):

United States ◽

Escherichia Coli ◽

Blot Analysis ◽

Southern Blot Analysis ◽

Medical Center ◽

Carbapenem Resistance ◽

The United States ◽

E Coli ◽

Tel Aviv ◽

Carbapenem Resistant

ABSTRACT Carbapenem resistance in Escherichia coli is rare. We report four genetically unrelated carbapenem-resistant E. coli isolates cultured from four patients hospitalized in Tel Aviv Medical Center. PCR, sequencing, and Southern blot analysis identified KPC-2 as the imipenem-hydrolyzing enzyme in all four strains, carried on different plasmids with a possible common origin. This is the first discovery of KPC-2 in E. coli and the first report of this enzyme originating outside the United States.

Download Full-text

Emergence of carbapenem-resistant ST131 Escherichia coli carrying blaOXA-244 in Germany, 2019 to 2020

Eurosurveillance ◽

10.2807/1560-7917.es.2020.25.46.2001815 ◽

2020 ◽

Vol 25 (46) ◽

Author(s):

Sybille Welker ◽

Sébastien Boutin ◽

Thomas Miethke ◽

Klaus Heeg ◽

Dennis Nurjadi

Keyword(s):

Escherichia Coli ◽

Carbapenem Resistance ◽

Health Concern ◽

Gram Negative Bacteria ◽

Public Health Concern ◽

Gram Negative ◽

E Coli ◽

Carbapenem Resistant ◽

South West ◽

Tertiary Hospitals

The dissemination of carbapenem-producing Gram-negative bacteria is a major public health concern. We report the first detection of OXA-244-producing ST131 O16:H5 Escherichia coli in three patients from two tertiary hospitals in the south-west of Germany. OXA-244 is emerging in Europe. Because of detection challenges, OXA-244-producing E. coli may be under-reported. The emergence of carbapenem resistance in a globally circulating high-risk clone, such as ST131 E. coli is of clinical relevance and should be monitored closely.

Download Full-text

Detection of Carbapenemase Production in Clinical Isolates of Escherichia coli and Klebsiella Species

International Journal of Current Microbiology and Applied Sciences ◽

10.20546/ijcmas.2021.1011.049 ◽

2021 ◽

Vol 10 (11) ◽

pp. 438-450

Author(s):

Harvinder Kaur Sneha Mohan ◽

Tarana Sarwat Dalip K. Kakru

Keyword(s):

Escherichia Coli ◽

Carbapenem Resistance ◽

Polymyxin B ◽

Clinical Isolates ◽

Resistant Bacteria ◽

Bacterial Strains ◽

Klebsiella Species ◽

Cross Sectional ◽

E Coli ◽

Carbapenem Resistant

The increasingly frequent application of carbapenemases induces a selective pressure on bacteria to acquire resistance against carbapenems. A large variety of carbapenemases have been identified in Enterobacteriaceae. The emergence of carbapenemases in E. coli and Klebsiella species possess a serious therapeutic problem in hospitals because carbapenems are often antibiotics of last resort for the treatment of serious infections caused by multidrug-resistant bacteria. The main aim of this study to determine the carbapenem-resistant strains of Escherichia coli and Klebsiella species. Detection of carbapenemase enzyme in the carbapenem-resistant Escherichia coli and Klebsiella species. This is a cross-sectional study, performed in the bacteriological laboratory. A total of 204 strains of Escherichia coli and 122 strains of Klebsiella species were isolated from patients admitted & attending the OPD at Sharda Hospital during the study period. The identification of the clinical isolates was based on morphological and biochemicals characterization. Result: Among the total number of bacterial growth received during the study period, the E. coli (204) was more in number as compared to other bacterial strains followed by Klebsiella species (122), Pseudomonas species (117), Staphylococcus aureus (100) and Enterococcus species (80). Among the following specimen i.e, urine (58.8%), was highly received during the study period followed by pus (15.3%) and sputum (7.5%). Colistin (100%) and Polymyxin B (100%) is found to be the most sensitive drug. Gentamicin (19.6%) and Cefuroxime (12.2%) are the least sensitive drugs. In the present study, we found that the Klebsiella species (75%) and Escherichia coli (64%) was the major reason of carbapenemase production but the organisms incidentally were susceptible to colistin and polymyxins (100%) followed by other antibiotics. This is a welcome finding in times of increasing carbapenem resistance & is reason enough to suggest the use of Polymyxins in the health care settings where the carbapenems to be used for the treatment of infections caused by Enterobacteriaceae.

Download Full-text

Complete genomic characterisation of two Escherichia coli lineages responsible for a cluster of carbapenem resistant infections in a Chinese hospital

10.1101/100941 ◽

2017 ◽

Cited By ~ 1

Author(s):

Zhiyong Zong ◽

Samuel Fenn ◽

Christopher Connor ◽

Yu Feng ◽

Alan McNally

Keyword(s):

Escherichia Coli ◽

Carbapenem Resistance ◽

Health Crisis ◽

West China Hospital ◽

E Coli ◽

Carbapenem Resistant ◽

Carbapenemase Gene ◽

Intergenic Regions ◽

Resistant Strains ◽

Drug Resistant Strains

AbstractThe increase in infections as a result of multi-drug resistant strains of Escherichia coli is a global health crisis. The emergence of globally disseminated lineages of E. coli carrying ESBL genes has been well characterised. An increase in strains producing carbapenemase enzymes and mobile colistin resistance is now being reported, but to date there is little genomic characterisation of such strains. Routine screening of patients within an ICU of West China Hospital identified a number of E. coli carrying the blaNDM-5 carbapenemase gene, found to be two distinct clones, E. coli ST167 and ST617. Interrogation of publically available data shows isolation of ESBL and carbapenem resistant strains of both lineages from clinical cases across the world. Further analysis of a large collection of publically available genomes shows that ST167 and ST617 have emerged in distinct patterns from the ST10 clonal complex of E. coli, but share evolutionary events involving switches in LPS genetics, intergenic regions and anaerobic metabolism loci. These may be evolutionary events which underpin the emergence of carbapenem resistance plasmid carriage in E. coli.

Download Full-text

Detection of Carbapenem-Resistant Genes in Escherichia coli Isolated from Drinking Water in Khartoum, Sudan

Journal of Environmental and Public Health ◽

10.1155/2020/2571293 ◽

2020 ◽

Vol 2020 ◽

pp. 1-6

Author(s):

Neama Esmat Mahmoud ◽

Hisham N. Altayb ◽

Reem Majzoub Gurashi

Keyword(s):

Escherichia Coli ◽

Drinking Water ◽

Treatment Options ◽

Tetracycline Resistance ◽

Carbapenem Resistance ◽

High Rate ◽

E Coli ◽

Carbapenem Resistant ◽

Resistant Genes ◽

First Time

Waterborne Escherichia coli are a major reservoir of antimicrobial resistance (AMR). Carbapenem-resistance, especially when mediated by transferable carbapenemase-encoding genes, is spreading worldwide and causing dramatically limiting treatment options. In our country, studies for the detection of carbapenem resistance in drinking water do not exist; therefore, this work was carried out to determine the prevalence of carbapenem-resistant genes “blaKPC, blaIMP, blaNDM, blaSPM, blaVIM, and blaOXA-48” among Escherichia coli isolated from drinking water in Khartoum, Sudan. A total of forty-five E. coli bacteria were isolated from different sources of drinking water. Antimicrobial susceptibility testing was performed using imipenem (10 mg/disc), gentamicin (10 mg/disc), ceftriaxone (30 mg/disc), ciprofloxacin (5 mg/disc), chloramphenicol (30 mg/disc), and tetracycline (30 mg/disc). “Sensitive” or “resistant” patterns of E. coli were judged using antibiotic minimum inhibitory concentration (MIC). Bacterial genomic DNA was extracted by the boiling method, and then multiplex polymerase chain reaction was performed to detect the carbapenemase genes (blaKPC, blaIMP, blaNDM, blaSPM, blaVIM, and blaOXA-48). Multiplex PCR assays confirmed the presence of carbapenemase genes in 28% of all water isolates. OXA-48 gene was the most predominant gene, detected in 15.5% of the isolates. The blaKPC and blaSPM genes were also detected in 4.4% and 8.8% of the isolates, respectively. However, the isolates were negative for blaNDM, blaVIM, and blaIMP genes. The isolates showed a high rate of tetracycline resistance (97.7%), followed by gentamicin (57.7%), ciprofloxacin (46.6%), ceftriaxone (35.5%), and chloramphenicol (31.1%). In conclusion, this study confirmed for the first time the presence of E. coli carried carbapenem-resistant genes in the drinking water of Khartoum state, Sudan. These isolates commonly carried OXA-48 (7/45), followed by SPM (4/45) and KPC (2/45).

Download Full-text